Top CDMO Stocks Compared: Divi’s Labs vs Syngene vs Sai Life Sciences vs Anthem Biosciences vs Neuland Labs on Price, Valuation, Q2 FY27 Results and Risks

Previous close: Divi’s Labs Rs 11,097.00, Syngene Rs 434.70, Sai Life Sciences Rs 1,744.00, Anthem Biosciences Rs 942.35, Neuland Labs Rs 19,836.00.

CDMO stocks compared here means Divi’s Labs, Syngene, Sai Life Sciences, Anthem Biosciences and Neuland Labs on one page, checked on previous close, market value, valuation and the latest quarterly numbers. All five serve global drug makers, but they differ in whether they make active ingredients, run research services or manufacture at commercial scale, which is exactly why a side-by-side look helps.

All five contract research and manufacturing companies have filed their September 2026 quarter, so every result below is Q2 FY27. Contract drug makers follow global pharma spending and outsourcing trends, so a glance at the BSE 500 page and the Sensex page before you read the tables gives useful backdrop.

Click Here – Get Free Investment Predictions

CDMO Stocks Compared: Five Contract Research and Manufacturing Names

The CDMO stocks compared here are Divi’s Labs, Syngene, Sai Life Sciences, Anthem Biosciences and Neuland Labs. Divi’s Labs is the largest by market capitalisation at Rs 3,07,147 crore. Previous closes run from Rs 434.70 for Syngene to Rs 19,836.00 for Neuland Labs, which is why a side-by-side look at value rather than price is more useful. This CDMO stocks compared list is the base for every table that follows.

Stock	Previous close (Rs)	Market cap (Rs crore)
Divi’s Labs	11,097.00	3,07,147
Syngene	434.70	17,638
Sai Life Sciences	1,744.00	39,005
Anthem Biosciences	942.35	54,032
Neuland Labs	19,836.00	26,074

A quick look at the business behind each ticker puts the numbers in context. Divi’s Labs makes active pharmaceutical ingredients and intermediates and offers custom synthesis for global drug companies, while Syngene offers drug discovery, development and manufacturing services to global pharma and biotech clients. Sai Life Sciences offers discovery, development and manufacturing services for global drug makers, and Anthem Biosciences offers research, development and manufacturing services for drug and biotech companies. To compare CDMO stocks properly, line up price to earnings, return on equity and operating margin before forming a view.

Rounding out the group, Neuland Labs makes active pharmaceutical ingredients and offers custom manufacturing for global clients. A fair CDMO stock comparison looks at what each company actually earns from, not only at the share price. Ingredient makers and research-led service firms belong in separate mental boxes whenever you compare CDMO stocks fairly.

CDMO Stocks Valuation: Premium Multiples and Returns

Neuland Labs trades at the lowest price to earnings ratio in this group at 57.62. It also reports the highest return on equity at 22.30%. Syngene has the lowest price to book value at 3.63. These CDMO stocks valuation readings come from the previous close and the latest reported financials. That is the idea behind this CDMO stocks compared table: price to earnings and return on equity sit side by side so a high or low reading stands out at once.

Stock	Price to earnings	Price to book	ROE (%)	Dividend yield (%)	Debt to equity
Divi’s Labs	91.33	17.07	15.32	0.26	0.00
Syngene	94.78	3.63	5.47	0.29	0.10
Sai Life Sciences	103.66	14.51	14.00		0.23
Anthem Biosciences	87.97	16.47	18.71	0.21	0.01
Neuland Labs	57.62	12.85	22.30	0.17	0.17

CDMO stocks usually trade at premium price to earnings multiples because investors pay for long customer contracts and high entry barriers. Return on equity and price to book help you judge whether that premium is earned. Earnings per share and book value per share are the building blocks behind price to earnings and price to book, so a glance at both in each filing is time well spent. A simple CDMO stock comparison like this one is only as useful as the context behind it, which is why operating margin is worth checking as well.

In this group, price to earnings runs from 57.62 for Neuland Labs to 103.66 for Sai Life Sciences. Syngene offers the highest dividend yield at 0.29%. Industry price to earnings readings differ by sub-sector: Divi’s Labs, Sai Life Sciences, Anthem Biosciences and Neuland Labs at 40.13; Syngene at 61.92. The industry price to earnings is a handy anchor: an CDMO stock above it is priced for faster growth, and one below it is priced for steadier earnings. A well-built CDMO stock comparison also notes that project timing can move results between quarters. Run the same CDMO stock comparison on your own watchlist and the pattern in these numbers will be easier to spot.

CDMO Stocks Q2 FY27 Results: Revenue and Profit Check

All of the five CDMO stocks compared have filed Q2 FY27 numbers. Divi’s Labs posted the fastest revenue growth at 31.8% year on year. Divi’s Labs showed the sharpest rise in net profit at 63.6%. Read revenue first and quarterly profit second, since the two together show how much of the growth reaches shareholders. Treat the Q2 FY27 numbers in this CDMO stocks compared review as a snapshot of one quarter, not a verdict on any contract drug maker.

Stock	Q2 FY27 revenue (Rs crore)	Q2 FY26 revenue (Rs crore)	Q2 FY27 net profit (Rs crore)	Q2 FY26 net profit (Rs crore)
Divi’s Labs	3,770	2,860	1,127	689.0
Syngene	860.7	926.0
Sai Life Sciences	662.6	552.8	98.3	83.8
Anthem Biosciences	652.9	598.3	211.5	173.4
Neuland Labs	457.2	516.1

Divi’s Labs Results Snapshot

Divi’s Labs’ Q2 FY27 top line stood at Rs 3,770 crore, versus Rs 2,860 crore in Q2 FY26, a rise of 31.8%. Net profit rose 63.6% to Rs 1,127 crore from Rs 689.0 crore. Operating margin expanded to 45.2% from 38.0% a year ago. Earnings per share for the quarter rose to Rs 42.49 from Rs 25.97.

Syngene Results Snapshot

Syngene reported Q2 FY27 revenue of Rs 860.7 crore for the September 2026 quarter.

Sai Life Sciences Results Snapshot

In the September 2026 quarter, Sai Life Sciences booked revenue of Rs 662.6 crore against Rs 552.8 crore in the same quarter last year, a rise of 19.9%. Net profit rose 17.3% to Rs 98.3 crore from Rs 83.8 crore. Earnings per share for the quarter rose to Rs 4.58 from Rs 3.93.

Anthem Biosciences Results Snapshot

Anthem Biosciences’ Q2 FY27 top line stood at Rs 652.9 crore, versus Rs 598.3 crore in Q2 FY26, a rise of 9.1%. Net profit rose 21.9% to Rs 211.5 crore from Rs 173.4 crore. Operating margin expanded to 55.6% from 48.4% a year ago. Earnings per share for the quarter rose to Rs 3.72 from Rs 3.09.

Neuland Labs Results Snapshot

Neuland Labs reported Q2 FY27 revenue of Rs 457.2 crore for the September 2026 quarter.

CDMO results depend on project timing, capacity use and the mix of research and manufacturing work, so profit can look different from revenue in a single quarter. That is why an CDMO stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, an CDMO stocks compared review becomes a map of the sector rather than a price list. When you compare CDMO stocks after each result season, track how operating margin changes from one quarter to the next.

CDMO Stocks Compared Two at a Time: Three Pairings

Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare CDMO stocks two at a time.

Divi’s Labs vs Neuland Labs

Divi’s Labs and Neuland Labs both make active pharmaceutical ingredients and offer custom synthesis, so they are the natural pair for anyone who wants exposure to ingredient makers. Divi’s Labs is about 11.8 times the size of Neuland Labs by market capitalisation, at Rs 3,07,147 crore against Rs 26,074 crore. Neuland Labs reports the higher return on equity, at 22.30% against 15.32% for Divi’s Labs. For dividend income, Divi’s Labs offers 0.26% against 0.17% at Neuland Labs. A larger ingredient maker and a smaller one are priced differently, so read growth next to valuation before you judge either multiple.

Syngene vs Sai Life Sciences

Syngene and Sai Life Sciences both offer discovery, development and manufacturing services, so they give exposure to research-led outsourcing. Sai Life Sciences is about 2.2 times the size of Syngene by market capitalisation, at Rs 39,005 crore against Rs 17,638 crore. On price to earnings, Syngene carries the lower multiple at 94.78 against 103.66 for Sai Life Sciences. Sai Life Sciences reports the higher return on equity, at 14.00% against 5.47% for Syngene. Both depend on global biotech funding, so read order commentary next to returns.

Anthem Biosciences vs Syngene

Anthem Biosciences and Syngene both offer research, development and manufacturing services for drug and biotech firms. On price to earnings, Anthem Biosciences carries the lower multiple at 87.97 against 94.78 for Syngene. Anthem Biosciences reports the higher return on equity, at 18.71% against 5.47% for Syngene. For dividend income, Syngene offers 0.29% against 0.21% at Anthem Biosciences. A newer listed name and an established one are priced differently, so read returns and valuation together.

Best CDMO Stocks for Each Type of Investor

Searching for the best CDMO stocks usually means different things to different readers. The table below shows who leads on each measure today, so you can pick the row that matches your goal. Any CDMO stocks compared table can mislead if you stop at one row, because each contract drug maker leads on a different measure.

If you care most about	Start your research with	The number
Lowest price to earnings	Neuland Labs	57.62
Highest return on equity	Neuland Labs	22.30%
Highest dividend yield	Syngene	0.29%
Lowest price to book value	Syngene	3.63
Largest by market capitalisation	Divi’s Labs	Rs 3,07,147 crore
Fastest Q2 FY27 revenue growth	Divi’s Labs	31.8%
Sharpest Q2 FY27 net profit rise	Divi’s Labs	63.6%

No single name tops every row, which is exactly why an CDMO stock comparison helps. Scale, returns, growth and valuation each point to a different company, so decide what matters most to you before you rank the numbers.

What Is Driving Contract Drug Research and Manufacturing Right Now?

Global drug makers are outsourcing more research and manufacturing, and many are adding partners outside a single country. Indian contract firms gain from a large pool of scientists and a long record with regulators. Knowing what moves project timing and customer orders helps you compare CDMO stocks with the right questions in mind.

Project wins, capacity use and the mix of high-value work decide margins. Companies that move from small batches to commercial supply can earn steadier income over long contracts. A good CDMO stocks compared routine therefore tracks order book, capacity use and customer mix.

Risks to Weigh When You Compare CDMO Stocks

CDMO stocks depend on a few large customers, regulatory inspections and the pace of new orders. Project timing can make quarterly numbers uneven. Read each filing for order book, capacity and customer commentary before you compare them. Every CDMO stock comparison has blind spots, and for this group the biggest is project timing and customer orders.

Because order book, capacity use and customer mix drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this CDMO stocks compared guide a balanced starting point.

How to Compare CDMO Stocks and Build a Shortlist

Start by deciding whether you want ingredient makers, research-led service firms or a blend of both, because each responds to different triggers. Ingredient makers reward readers who track plant use and large customers, while research firms reward those who track project wins. Done step by step, this CDMO stocks compared routine becomes repeatable rather than a one-off exercise.

Then check valuation and returns, because premium multiples leave less room for slips and project timing can make quarters uneven. Spreading your attention across one ingredient maker and one research-led firm is a simple way to see both sides of the sector. Keep the shortlist of best CDMO stocks short enough that you can actually follow each company’s quarterly results. When you compare CDMO stocks again after new results, update only the rows that changed instead of starting over.

The Univest stock screener lets you filter CDMO stocks by market capitalisation, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this CDMO stocks compared page after the next set of results to see which numbers have moved.

Check the Univest Screener for live CDMO stock data

Download the Univest iOS App or Univest Android App to track these CDMO stocks live.

Conclusion: CDMO Stocks Compared at a Glance

This CDMO stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Divi’s Labs leads on size and Neuland Labs leads on return on equity, while the others bring their own strengths. Treat the CDMO stocks Q2 FY27 results and CDMO stocks valuation tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare CDMO stocks again next quarter, the same checklist of price to earnings, return on equity and operating margin will work.

Frequently Asked Questions on CDMO Stocks Compared

Which are the top CDMO stocks compared in this article?

Ans. The CDMO stocks compared in this article are Divi’s Labs, Syngene, Sai Life Sciences, Anthem Biosciences and Neuland Labs. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, which gives you one tidy table to work from before you read any filing in detail.

Which CDMO stock has the highest market capitalisation?

Ans. Among the five names, Divi’s Labs has the highest market capitalisation at Rs 3,07,147 crore. Anthem Biosciences follows at Rs 54,032 crore. Because market capitalisation is simply share price multiplied by shares outstanding, it shifts daily, so confirm the live number before using it.

Which of these CDMO stocks has the lowest price to earnings ratio?

Ans. On CDMO stocks valuation, Neuland Labs has the lowest price to earnings ratio among these CDMO stocks at 57.62, based on the latest reported earnings. Sai Life Sciences sits at the other end at 103.66. A low multiple can reflect slower growth or higher risk as easily as a bargain, so read it next to growth and margins.

Which CDMO stock has the highest return on equity?

Ans. Neuland Labs reports the highest return on equity in this group at 22.30%. The ratio measures profit earned for every rupee of shareholder money, which makes it a quick test of capital efficiency. One year can mislead, so look at several, and remember that borrowing can push the figure up.

How did CDMO stocks perform in Q2 FY27 results?

Ans. All of the five names have filed Q2 FY27 numbers in our data. Divi’s Labs recorded the fastest revenue growth at 31.8% year on year. Divi’s Labs showed the sharpest net profit rise at 63.6%. For CDMO stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.

What are the main risks when you compare CDMO stocks?

Ans. CDMO stocks depend on a few large customers, regulatory inspections and the pace of new orders. Project timing can make quarterly numbers uneven. Read each filing for order book, capacity and customer commentary before you compare them. Keep an eye on order book, capacity use and customer mix.

Which metrics matter most when you compare CDMO stocks?

Ans. Order book, capacity use, customer mix and operating margin matter most for operating performance. Price to earnings, return on equity and price to book show how the market values each company. Read each company’s filing for these along with the numbers in this article.

Which is the best CDMO stock to buy among these five?

Ans. The best CDMO stock depends on whether you value ingredient making, research services or commercial manufacturing, because the five names differ on all three. On the numbers in this article, Divi’s Labs has the largest market capitalisation; Neuland Labs has the lowest price to earnings as well as the highest return on equity; Syngene has the highest dividend yield. Each name wins on a different row, and this is educational content rather than advice. Build a shortlist from the tables, read the latest filings, and talk to a SEBI-registered advisor, because your own goals and risk appetite decide the right fit.